
FDA gives a mixed response to petition seeking greater clinical trial transparency
The U.S. Food and Drug Administration stated that it does not plan to impose stricter penalties against clinical trial sponsors and researchers who fail to register studies or report results. This decision is based on potential strain on resources. The agency prefers to rely on voluntary compliance and retains the right to exercise regulatory discretion…